JP2010533132A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533132A5
JP2010533132A5 JP2010515363A JP2010515363A JP2010533132A5 JP 2010533132 A5 JP2010533132 A5 JP 2010533132A5 JP 2010515363 A JP2010515363 A JP 2010515363A JP 2010515363 A JP2010515363 A JP 2010515363A JP 2010533132 A5 JP2010533132 A5 JP 2010533132A5
Authority
JP
Japan
Prior art keywords
diseases
cancer
treatment
carcinoma
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010515363A
Other languages
English (en)
Japanese (ja)
Other versions
JP5457343B2 (ja
JP2010533132A (ja
Filing date
Publication date
Priority claimed from DE102007032739A external-priority patent/DE102007032739A1/de
Application filed filed Critical
Publication of JP2010533132A publication Critical patent/JP2010533132A/ja
Publication of JP2010533132A5 publication Critical patent/JP2010533132A5/ja
Application granted granted Critical
Publication of JP5457343B2 publication Critical patent/JP5457343B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010515363A 2007-07-13 2008-06-16 キナゾリンアミド誘導体 Expired - Fee Related JP5457343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007032739.2 2007-07-13
DE102007032739A DE102007032739A1 (de) 2007-07-13 2007-07-13 Chinazolinamidderivate
PCT/EP2008/004846 WO2009010139A2 (de) 2007-07-13 2008-06-16 Chinazolinamidderivate

Publications (3)

Publication Number Publication Date
JP2010533132A JP2010533132A (ja) 2010-10-21
JP2010533132A5 true JP2010533132A5 (cg-RX-API-DMAC10.html) 2013-12-05
JP5457343B2 JP5457343B2 (ja) 2014-04-02

Family

ID=40121496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515363A Expired - Fee Related JP5457343B2 (ja) 2007-07-13 2008-06-16 キナゾリンアミド誘導体

Country Status (15)

Country Link
US (1) US8501754B2 (cg-RX-API-DMAC10.html)
EP (1) EP2164833B1 (cg-RX-API-DMAC10.html)
JP (1) JP5457343B2 (cg-RX-API-DMAC10.html)
KR (1) KR20100044846A (cg-RX-API-DMAC10.html)
CN (1) CN101743229B (cg-RX-API-DMAC10.html)
AR (1) AR067506A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008278032B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0814236A2 (cg-RX-API-DMAC10.html)
CA (1) CA2694475C (cg-RX-API-DMAC10.html)
DE (1) DE102007032739A1 (cg-RX-API-DMAC10.html)
EA (1) EA017585B1 (cg-RX-API-DMAC10.html)
ES (1) ES2538218T3 (cg-RX-API-DMAC10.html)
IL (1) IL203206A (cg-RX-API-DMAC10.html)
WO (1) WO2009010139A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201001058B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008061214A1 (de) 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CA2779681A1 (en) * 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
DE102009054302A1 (de) * 2009-11-23 2011-05-26 Merck Patent Gmbh Chinazolinderivate
DE102010046837A1 (de) * 2010-09-29 2012-03-29 Merck Patent Gmbh Phenylchinazolinderivate
EA023821B1 (ru) * 2010-11-24 2016-07-29 Мерк Патент Гмбх Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
TW201311149A (zh) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
MX2015012600A (es) * 2013-03-15 2016-07-18 Rexahn Pharmaceuticals Inc Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
HK1255074A1 (zh) * 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US11374044B2 (en) * 2016-07-19 2022-06-28 Nippon Kayaku Kabushiki Kaisha Material for photoelectric conversion element for use in imaging element, and photoelectric conversion element including same
KR102665544B1 (ko) * 2017-06-26 2024-05-14 선샤인 레이크 파르마 컴퍼니 리미티드 디하이드로피리미딘 화합물 및 약제에서의 이의 용도
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗盆腔炎的化合物及制备方法和应用
CN107488168A (zh) * 2017-07-18 2017-12-19 黄绍菊 一种治疗盆腔炎的化合物及制备方法和应用
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
TWI853814B (zh) 2018-05-31 2024-09-01 南韓商C&C新藥研究所 雜環衍生物及其用途
WO2022015938A1 (en) * 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
TW202400600A (zh) * 2022-06-16 2024-01-01 美商昂勝醫療科技股份有限公司 喹唑啉衍生物、其組成物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU776652B2 (en) 1999-03-12 2004-09-16 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of inhibiting a chaperone protein
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
EP1322325A4 (en) 2000-07-20 2004-09-15 Merck & Co Inc INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
WO2002083648A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
AU2005266494B2 (en) 2004-07-27 2009-09-10 Novartis Ag Inhibitors of Hsp90
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate

Similar Documents

Publication Publication Date Title
JP2010516639A5 (cg-RX-API-DMAC10.html)
Kunnumakkara et al. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
JP2011102304A5 (cg-RX-API-DMAC10.html)
Altieri Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis
CN113784963A (zh) 用作ret激酶抑制剂的化合物及其应用
JP2019524883A5 (cg-RX-API-DMAC10.html)
MX2019001302A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
TW200640883A (en) Compounds for the treatment of proliferative disorders
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
BRPI0916356A2 (cg-RX-API-DMAC10.html)
EP3119754A1 (en) Antifungal compound process
WO2009066060A3 (en) 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
JP2013521291A5 (cg-RX-API-DMAC10.html)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
Huo et al. 2‑Arylindoles: Concise Syntheses and a Privileged Scaffold for Fungicide Discovery
EA202090259A1 (ru) Новые гетероариламидные производные как селективные ингибиторы гистондеацетилаз 1 и/или 2 (hdac1-2)
TNSN07294A1 (en) Treatment of metastasized tumors
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
TW200716570A (en) Compounds for the treatment of proliferative disorders
MX2024002409A (es) Terapias contra el cancer.
Movafagh et al. Histone deacetylase inhibitors in cancer prevention and therapy
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
Hassan et al. Synthesis and pharmacological profiling of mono imine Schiff bases: Dual anti-inflammatory and antibacterial activity with computational insights
JP2017511340A5 (cg-RX-API-DMAC10.html)
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments